ClinicalTrials.gg
Active, not recruitingNCT06058598HIT GLAUCOMAUpdated Dec 17, 2025

Exercise Training in Patients With Glaucoma

An interventional study of Exercise Training and Lifestyle Counselling in Glaucoma, Open-Angle, Exercise Training and Microvascular Health, sponsored by Henner Hanssen. Active, not recruiting at 1 site in Switzerland. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Henner Hanssen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Glaucoma, Open-Angle with a site in Switzerland — 1 open to participants now, 4 under way, none of them phase 3. Glaucoma, Open-Angle · Switzerland.

Planned enrollment
5th of 17
168 · median 50
Started
2023
the only one that year
No phase
14 of 24
none open now
Registered
24th of 24
by date

Among the 24 studies in Glaucoma, Open-Angle with a site in Switzerland, this one is the 5th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2023, is one of 14 with no phase, and was the 24th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 24 studies in Glaucoma, Open-Angle with a site in Switzerland is open now. Recruiting first, the newest first:

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Glaucoma, Open-Angle with a site in Switzerland, or all of them as a file.
02

Study summary

HIT GLAUCOMA is a multicenter exercise study for glaucoma patients between three institutes: the Department of Sport, Exercise and Health (DSBG) of the University of Basel, the Eye Clinic at the University Hospital Basel and the UZ Leuven (Belgium). The main objective of the study is to investigate the possibility of using exercise therapy to treat glaucoma. Participants will be randomly divided into two groups: Intervention and Control group. The intervention group will receive a high-intensity interval training plan, and the control group will receive lifestyle counseling and standard therapy. With this method, the study aims to validate an exercise therapy concept that could significantly improve disease progression and quality of life in patients with glaucoma.

Read the detailed description

Approximately 57.5 million people are affected by primary open-angle glaucoma, and it is estimated that this number will increase to 111.8 million by 2040. Despite the high prevalence and critical outlook of the disease, the pathogenesis of glaucoma is still not fully understood and treatment options remain inadequate. In particular, for glaucoma with normal intraocular pressure, there is as yet no evidence-based effective treatment option. This particular type of glaucoma may, in part, be the result of impaired microvascular endothelial function. Physical training has a proven effect on vascular health; because glaucoma involves a vascular component, positive effects of high-intensity interval training can be assumed. Thus, it could be an effective treatment for glaucoma disease.

Patients will be randomly assigned to either the intervention or control group. Patients assigned to the intervention group will participate in a 6-month exercise training program followed by a 6-months non-supervised and home-based physical activity maintenance program. During the first 6 months, patients in the intervention group participate in 18 supervised exercise sessions at the DSBG, interspersed by unsupervised exercise interventions at home.

All patients will be seen at baseline, after three months and six months of aerobic exercise training, and after another six months of physical activity and exercise self-maintenance (intervention group) or control condition. Each subject will be asked to undergo standard ophthalmic examination, non-invasive retinal assessments, peripheral blood withdrawal, and additional peripheral vascular examinations. The study design is based on regular glaucoma follow-up intervals (every 6 months) and does not intervene with clinical care and governmental reimbursement of standard care. Patients will finish their study participation after 6 months of exercise training followed by 6 months of physical activity and exercise self-maintenance or control condition.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Exercise Training
  • Microvascular Health

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written of the participant has been obtained prior to any screening procedures
  • Patients with primary open angle glaucoma (POAG), high tension glaucoma (HTG) and normal tension glaucoma (NTG), aged 40 - 75 years
  • In regular follow-up in either of the two study centres

Exclusion criteria

Exclusion Criteria:

  • Patients having had glaucoma surgery within 6 months before start of the project
  • Patients with changes in topical medication or laser trabeculoplasty within 3 months before start of the project
  • Patients with very severe glaucoma (visual field mean deviation lower than -12Db)
  • Significant opacification of ocular media
  • Patients with life-threatening arrhythmia, signs of ischemia during CPET which preclude participation in an exercise trial
  • Patients with insulin treated diabetes, or cancer.
  • Patients doing ≥1 structured exercise training session per week or >150min of exercise/week assessed via the following two questions: a. On average, how many days per week do you engage in moderate to vigorous physical activity (like brisk walking)? b. On average, how many minutes per day do you engage in physical activity at this level? Calculate the total weekly minutes of exercise by multiplying a times b.
  • Mental or physical limitation precluding participation in a high intensity exercise program
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Group performing exercise training and receiving standard care

    Other: Exercise Training

  • Experimental
    Control Group

    Group receiving lifestyle counseling and receiving standard care

    Other: Lifestyle Counselling

Interventions

  • OtherExercise Training

    6-months supervised exercise training + 6 months unsupervised exercise training

  • OtherLifestyle Counselling

    12-months of lifestyle counselling

06

What researchers measure

Primary outcomes

  1. Microvascular health: retinal arteriolar and venular dilation and diameters

    Retinal arteriolar and venular flicker light-induced dilation after six months; Retinal arteriolar and venular diameters after six months

    Time frame: 6-months

07

Study locations

1 site
08

References and documents

Publications

  • Van Eijgen J, Schuhmann V, Fingerroos EL, Renier M, Burchert H, Kropfl JM, Van Craenenbroeck A, Cornelissen V, Gugleta K, Stalmans I, Hanssen H. High-intensity interval training in patients with glaucoma (HIT-GLAUCOMA): protocol for a multicenter randomized controlled exercise trial. Front Physiol. 2024 May 16;15:1349313. doi: 10.3389/fphys.2024.1349313. eCollection 2024. PubMed 38818519 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Mar 2026, 27 months after the start.

Of 101 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 27 months is below that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 28, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Mar 31, 2026
CompletionEst.
Sep 30, 2026
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06058598
Lead sponsor
Henner Hanssen
Responsible party
Henner Hanssen (Professor, University of Basel) — Sponsor-investigator
First posted
Sep 28, 2023
Start date
Dec 1, 2023
Primary completion
Mar 31, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Dec 17, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion